The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry of Health, Labour and Welfare (MHLW) and supports Quoin's long-term commercial plans in one of its three core markets.

A local corporate presence allows Quoin to engage directly with Japanese regulators, clinicians, and patient advocacy organizations as it builds the commercial infrastructure to support a potential launch. Japan is one of Quoin's core territories, along with the United States and Western Europe, in which Quoin intends to self-commercialize QRX003 and its other pipeline products. Outside of these territories, Quoin has established nine commercial partnerships for QRX003 spanning sixty one countries, which combined with the company's core territories, could facilitate almost global availability of the product if approved.

QRX003 has now received Orphan Drug Designation for Netherton Syndrome in the United States, the European Union, and Japan, providing development and commercial incentives across all three of Quoin's core commercial territories.